• Sleep · Oct 2014

    Controlled Clinical Trial

    Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening.

    • Patricia Rubio-Sastre, Frank A J L Scheer, Purificación Gómez-Abellán, Juan A Madrid, and Marta Garaulet.
    • Department of Physiology, University of Murcia, IMIB-Arrixaca, Murcia, Spain.
    • Sleep. 2014 Oct 1;37(10):1715-9.

    Study ObjectivesTo study the effect of melatonin administration on glucose metabolism in humans in the morning and evening.DesignPlacebo-controlled, single-blind design.SettingLaboratory assessments.Participants21 healthy women (24 ± 6 y; body mass index: 23.0 ± 3.3 kg/m(2)).InterventionsGlucose tolerance was assessed by oral glucose tolerance tests (OGTT; 75 g glucose) on 4 occasions: in the morning (9 AM), and evening (9 PM); each occurring 15 minutes after melatonin (5 mg) and placebo administration on 4 non-consecutive days.Measurements And ResultsMelatonin administration impaired glucose tolerance. When administered in the morning, melatonin significantly increased the incremental area under the curve (AUC) and maximum concentration (Cmax) of plasma glucose following OGTT by 186% and 21%, respectively, as compared to placebo; while in the evening, melatonin significantly increased glucose AUC and Cmax by 54% and 27%, respectively. The effect of melatonin on the insulin response to the OGTT depended on the time of day (P < 0.05). In the morning, melatonin decreased glucose tolerance primarily by decreasing insulin release, while in the evening, by decreasing insulin sensitivity.ConclusionsAcute melatonin administration in humans impairs glucose tolerance in both the morning and evening. When administering melatonin, the proximity to meal timing may need to be considered, particularly in those at risk for glucose intolerance.© 2014 Associated Professional Sleep Societies, LLC.

      Pubmed     Free full text   Copy Citation  

      Add institutional full text...

    Notes

    hide…